Caption Management, LLC Akero Therapeutics, Inc. Call Options Transaction History

Caption Management, LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$17.76 - $31.18 $401,376 - $704,668	22,600 Added 82.48%	50,000 $1.26 Million
Q4 2023 Feb 14, 2024	SELL	$11.38 - $50.33 $2.02 Million - $8.95 Million	-177,900 Reduced 86.65%	27,400 $639,000
Q3 2023 Nov 14, 2023	BUY	$41.19 - $52.25 $7.05 Million - $8.95 Million	171,200 Added 502.05%	205,300 $10.4 Million
Q2 2023 Aug 14, 2023	BUY	$36.89 - $56.88 $151,249 - $233,208	4,100 Added 13.67%	34,100 $1.59 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $50.24 $1.12 Million - $1.51 Million	30,000 New	30,000 $1.15 Million
Q3 2022 Nov 14, 2022	BUY	$10.15 - $34.05 $1.08 Million - $3.62 Million	106,300 New	106,300 $3.62 Million

170

72.7M

178K

164K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.38B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.